Trademark applications and grants for Astellas Pharma Inc. Astellas Pharma Inc has 222 trademark applications. The latest application filed is for "GI CANCER CHRONICLES"
Patent Application | Date |
---|---|
GENETICALLY ENGINEERED ONCOLYTIC VACCINIA VIRUSES AND METHODS OF USES THEREOF 20220290179 - 17/632686 Nakao; Shinsuke ;   et al. | 2022-09-15 |
GUIDE RNA FOR EDITING TARGET, WITH FUNCTIONAL NUCLEOTIDE SEQUENCE ADDED 20220275359 - 17/631727 YOSHIMI; Eiji ;   et al. | 2022-09-01 |
Granular Pharmaceutical Composition 20220257696 - 17/736243 Nishiura; Mare ;   et al. | 2022-08-18 |
METHOD FOR TREATING MUSCULAR DYSTROPHY BY TARGETING DMPK GENE 20220233721 - 17/614461 YOSHIMI; Eiji ;   et al. | 2022-07-28 |
NANOPARTICLE, CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING COMPRISING SAME AND ZWITTERIONIC LIGAND COMPOUND 20220184236 - 17/418142 Mizutani; Tsuyoshi ;   et al. | 2022-06-16 |
NCAGE Code | SAGS7 | ASTELLAS PHARMA INC. |
CAGE Code | SAGS7 | ASTELLAS PHARMA INC. |
SEC | 0001446390 | Astellas Pharma Inc of JAPAN |
SEC | 0001376684 | Astellas Pharma Inc. |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.